Stay updated on Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T16:34:00.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says both “Super Intelligence” and “Artificial Intelligence” may appear in NIH content during the transition.
    Difference
    1%
    Check dated 2026-10-26T16:51:48.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-19T21:55:53.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The site footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T04:24:17.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    Access to the study record is blocked by a 403 Forbidden error; the page now shows a minimal header with a 403 message instead of displaying the trial details and associated documents. This prevents users from reviewing the study design, eligibility criteria, locations, and results.
    Difference
    19%
    Check dated 2026-09-21T22:47:26.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A new publication citation was added for the Penelope-B trial: ‘Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort’ in Mod Pathol (2026), with full bibliographic details including authors and DOI (10.1016/j.modpat.2026.101006).
    Difference
    0.1%
    Check dated 2026-09-14T19:42:02.000Z thumbnail image

Stay in the know with updates to Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.